Wave Life Sciences, Inc. (WVE) Form 8-K — Oct 27, 2026
Wave Life Sciences reported Q3 2026 results on October 27, 2026, with revenue of $13.2 million (up from $7.6 million a year ago) and a net loss of $61.9 million, wider than the prior year's $53.9 million loss. The headline item is FDA alignment on a registrational pathway for WVE-006 in AATD, with a two-year trial supporting potential full approval and a one-year interim analysis for potential accelerated approval. The company also advanced WVE-007 (obesity) across three treatment settings and said GSK selected a development candidate using Wave's SpiNA siRNA design, triggering a $12 million milestone due in 4Q 2026.
Key figures
- Revenue
- 13158000
- Guidance
- Cash runway into 3Q 2028; $12M GSK milestone expected in 4Q 2026; WVE-008 CTA filing on track for 4Q 2026
- Revenue Yoy
- 73% increase vs $7.6M prior year quarter
- Total Assets
- 507930000
- Cash Position
- 431000000
- Ga expense q3
- 25362000
- Rd expense q3
- 53843000
- Gsk milestone upcoming
- 12000000
- Gsk max milestones per program
- $330-$375 million per collaboration program
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.